Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

BACKGROUND: Sofosbuvir plus ribavirin (SOF+RBV) for 12 weeks is the standard treatment for chronic hepatitis C (CHC) genotype 2 (GT2) in most of Asia despite availability of new CHC medications. SOF-RBV real-world effectiveness has only been reported in small and/or single-centre studies. Our goal w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Bin, Ji, Fanpu, Yeo, Yee Hui, Ogawa, Eiichi, Zou, Biyao, Stave, Christopher D, Dang, Shuangsuo, Li, Zongfang, Furusyo, Norihiro, Cheung, Ramsey C, Nguyen, Mindie H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Meta Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038840/
https://www.ncbi.nlm.nih.gov/pubmed/30002863
http://dx.doi.org/10.1136/bmjgast-2018-000207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038840/
https://www.ncbi.nlm.nih.gov/pubmed/30002863
http://dx.doi.org/10.1136/bmjgast-2018-000207

Ejemplares similares